Opinion
Video
SunRISe-1 and NURE-COMBO: Addressing Unmet Needs and Expanding Treatment Options for Bladder Cancer
Author(s):
Neal Shore, MD, FACS, discusses how the SunRISe-1 trial design addresses the need for bladder-sparing treatment options for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer (HR NMIBC) who are ineligible for or refuse radical cystectomy. He also contrasts the treatment approach and outcomes observed in the NURE-COMBO trial with the current standard neoadjuvant chemotherapy plus radical cystectomy regimen for muscle-invasive bladder cancer (MIBC), discussing how this chemoimmunotherapy combination may potentially expand treatment options for this patient population.
Video content above is prompted by the following question(s):
- How does the SunRISe-1 trial design address the need for bladder-sparing treatment options for patients with BCG-unresponsive HR NMIBC who are ineligible or refuse radical cystectomy? Discuss the rationale for investigating the combination of TAR-200 and cetrelimab, as well as the TAR-200 and cetrelimab monotherapy approaches, in this patient population and how the preliminary results from the combination cohort compare to the monotherapy cohorts.
- Contrast the treatment approach and outcomes observed in the NURE-COMBO trial with the current standard neoadjuvant chemotherapy plus radical cystectomy regimen for MIBC. How might this chemoimmunotherapy combination potentially expand treatment options for this patient population?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
